Biomarkers and risk factors for the early prediction of immune-related adverse events: a review

In recent years, immunotherapy has been widely used to treat patients with malignant tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of cancer patients, the incidence of immune-related adverse events (irAEs) is increasing. Not only can irAEs accumulate in multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Zhang, Xiaoling, Li, Weiling, Du, Yunyi, Hu, Wenqing, Zhao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Clinical – Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986173/
https://www.ncbi.nlm.nih.gov/pubmed/35108160
http://dx.doi.org/10.1080/21645515.2021.2018894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986173/
https://www.ncbi.nlm.nih.gov/pubmed/35108160
http://dx.doi.org/10.1080/21645515.2021.2018894

Ejemplares similares